₹662.40
−0.57%NSE close, 16 Nov 2026
+26.63%
Indegene is a small cap company in the Healthcare sector, listed on NSE under the symbol INDGN. At ₹662.40 a share, the market values the whole company at ₹15,962 crore.
In FY26, it reported sales of ₹3,511 crore and a net profit of ₹401 crore, an operating margin of 17.6%.
The market values the company at 38.8 times its profit over the last twelve months and 4.75 times its book value; its return on equity is 12.2% and it has almost no borrowings.
Promoters hold 0.00% of the shares. Foreign institutions hold 12.40%, and domestic institutions, mutual funds among them, 15.82%.
Over the past year the share price has risen 25.0%, and it is 2.2% below its 52-week high.
Companies of a similar size in the same sector include Caplin Point Laboratories, Syngene International, Cohance Lifesciences and Pfizer.
₹ crore. Consolidated figures.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Indegene | ₹662.40 | ₹15,962 cr | 38.8 | 12.2% | +39.60% | +24.95% |
| Caplin Point Laboratories | ₹2,346.80 | ₹17,838 cr | 25.9 | 17.7% | +17.90% | +17.08% |
| Syngene International | ₹441.20 | ₹17,810 cr | 95.7 | 3.8% | −8.60% | −28.91% |
| Cohance Lifesciences | ₹457.60 | ₹17,508 cr | 369.6 | 1.2% | −14.20% | −36.78% |
| Pfizer | ₹3,818.30 | ₹17,468 cr | 20.3 | 19.6% |
Schedule of meet
Transcript
Link of Recording
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 673 | 677 | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 | 1,122 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 534 | 548 | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 | 937 |
| Operating profit | 139 | 129 | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 | 186 |
| Operating margin | 20.6% | 19.1% | 18.4% | 18.3% | 19.5% | 20.4% | 17.5% | 16.9% | 16.3% | 16.4% | 16.5% |
| Other income | 23.2 | 22.5 | 21.4 | 37.7 | 25.6 | 22.1 | 19.7 | 19.4 | 10.8 | 29.0 | 15.0 |
| Interest | 12.3 | 11.7 | 4.0 | 3.2 | 3.1 | 3.7 | 3.8 | 4.6 | 7.2 | 6.4 | 6.9 |
| Depreciation | 18.5 | 20.1 | 19.4 | 20.0 | 20.7 | 21.6 | 23.4 | 39.6 | 41.8 | 44.1 | 46.4 |
| Profit before tax | 134 | 120 | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 | 147 |
| Tax | 38.7 | 31.9 | 32.4 | 36.6 | 31.7 | 35.7 | 31.0 | 31.8 | 25.4 | 36.5 | 35.1 |
| Net profit | 96.6 | 87.7 | 91.7 | 110 | 118 | 116 | 102 | 103 | 79.7 | 116 | 112 |
| EPS (₹) | 4.27 | 3.79 | 3.84 | 4.59 | 4.91 | 4.86 | 4.26 | 4.29 | 3.32 | 4.84 | 4.67 |
₹ crore, financial years to March.
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|
| From operations | 442 | 651 | −13.3 |
| From investing | −683 | −512 | −62.0 |
| From financing | 288 | −82.6 | −79.3 |
| Spent on fixed assets | −30.0 | −44.3 | −25.1 |
| Free cash flow | 412 | 607 | −38.4 |
Margins, returns, debt, tax and cash.
| Line | FY25 | FY26 |
|---|---|---|
| Net margin | 14.3% | 11.4% |
| Operating margin | 18.8% | 17.6% |
| Return on equity | 15.5% | 12.8% |
| Return on capital employed | 21.5% | 17.3% |
| Return on assets | 12.2% | 8.7% |
| Debt to equity | 0.00 | 0.00 |
| Interest coverage | 25.50 | 28.20 |
| Debt to assets | 0.00 | 0.00 |
| Current ratio | 4.48 | 2.41 |
| Quick ratio | 4.48 | 2.41 |
| Cash ratio | 0.43 | 0.28 |
| Asset turnover | 0.85 | 0.76 |
| Fixed asset turnover | 21.05 | 18.10 |
| Receivables turnover | 3.80 | 3.60 |
| Cash from operations to profit | 109.0% | 162.0% |
| Effective tax rate | 24.6% | 23.6% |
| +13.20% |
| −24.65% |
| Poly Medicure | ₹1,684.30 | ₹17,072 cr | 53.6 | 9.8% | +30.80% | −11.21% |
|---|
| Natco Pharma | ₹828.65 | ₹16,255 cr | 19.6 | 8.5% | −29.00% | +3.52% |
|---|
| Vijaya Diagnostic Centre | ₹1,487.50 | ₹15,321 cr | 75.2 | 19.3% | +26.70% | +46.11% |
|---|
| Jubilant Pharmova | ₹960.25 | ₹15,295 cr | 58.2 | 3.7% | +20.50% | −17.28% |
|---|
Indegene Delivers Strong Q2 FY27 Performance, H1 USD Revenue Growth Reaches a Four-Year High
Resignation of Ms Srishti Ramesh Kaushik as Company Secretary & Compliance Officer of the company w.e.f. December 02, 2026.
Allotment of 52194 securities pursuant to ESOP/ESPS at its meeting held on October 29, 2026
The financial results for the period ended September 30, 2026.
Indegene Receives Frost & Sullivan s 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization
Resignation of Mr Mark Francis Dzialga as Non- Executive Director of the company w.e.f. October 29, 2026.
Allotment of 16110 securities pursuant to ESOP Scheme 2020 of the Company
Indegene Digital Summit 2026 - National Constitution Center, Philadelphia